Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516136 | 0.95 | HPGD (0.71) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL28082736 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL28082834 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL28082801 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL4585546 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL8197547 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL4585892 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL3994188 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL9321740 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 | |
| SCHEMBL8210207 | 0.93 | TRPV1 (0.73) | HPGDGAAATMTRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173406-A1 | CHROMATOGRAPHIC COLUMNS AND SEPARATION DEVICES COMPRISING A SUPERFICIALLY POROUS MATERIAL; AND USE THEREOF FOR SUPERCRITICAL FLUID CHROMATOGRAPHY AND OTHER CHROMATOGRAPHY | WATERS TECHNOLOGIES CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210238565-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11015180-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-6117840-A | INHIBITS BINDING BETWEEN VLA-4 RECEPTOR EXPRESSED ON INFLAMMATORY LEUKOCYTES AND FIBRONECTIN CS-1 PEPTIDE EXPRESSED ON ENDOTHELIAL CELLS THAT ARE INVOLVED IN IMMUNOINFLAMMATORY DISEASE STATES | CYTEL CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0946495-A4 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000002903-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0946495-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5936065-A | PRODRUG AS ANTIINFLAMMATORY AGENT FOR AUTOIMMUNE DISEASES; FOR SUPPRESSING BINDING OF INFLAMMATORY CELLS TO ENDOTHELIAL CELLS THAT EXPRESS THE CS-1 PORTION OF FIBRONECTIN ON THEIR SURFACES | CYTEL CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| US-5770573-A | CS-1 peptidomimetics, compositions and methods of using the same | CYTEL CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998024756-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5688913-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS | CYTEL CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4143047-A | 2-SULFINYL AND 2-SULFONYL OXAZOLES | LILLY INDUSTRIES LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HPGD 365/4885GAA 2713/4885ATM 284/4885 |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HPGD 253/4885GAA 3274/4885ATM 284/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HPGD 365/4885GAA 2713/4885ATM 284/4885 |
| US-20230173406-A1 | CHROMATOGRAPHIC COLUMNS AND SEPARATION DEVICES COMPRISING A SUPERFICIALLY POROUS MATERIAL; AND USE THEREOF FOR SUPERCRITICAL FLUID CHROMATOGRAPHY AND OTHER CHROMATOGRAPHY | SPECC1L, CCL5, CCR5 | HPGD 717/4885GAA 2710/4885ATM 1377/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HPGD 2278/4885GAA 2581/4885ATM 2486/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | HPGD 2278/4885GAA 2581/4885ATM 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.